Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.